TY  - JOUR
T1  - Implementing high-value, cost-conscious diabetes mellitus care through the use of low-cost medications and less-intensive glycemic control target: Comment on "variation in use of high-cost diabetes mellitus medications in the va healthcare system"
AU  - Wilt TJ, Qaseem A
Y1  - 2012/11/12
N1  - 10.1001/2013.jamainternmed.203
JO  - Archives of Internal Medicine
SP  - 1610
EP  - 1611
VL  - 172
IS  - 20
N2  - 
Type 2 diabetes mellitus (DM) is a leading cause of morbidity and mortality, affecting nearly 26 million people and costing $174 billion in the United States.1 Monotherapy with oral agents lower hemoglobin A1c (HbA1c) levels an average of 1% of total hemoglobin. Combination therapy with a second oral medication or insulin leads to an additional 1% to 2% reduction. (To convert HbA1cto a proportion of total hemoglobin, multiply by 0.01.) Most people with type 2 DM will receive more than 1 class of medication: 14% take both insulin and oral medications, and 58% take multiple oral DM medications.1

SN  - 0003-9926
M3  - doi: 10.1001/2013.jamainternmed.203
UR  - http://dx.doi.org/10.1001/2013.jamainternmed.203
ER  -